CytoDyn Inc (OTCMKT: CYDY) has been under considerable selling pressure since April and nothing seems to be able to stop it. In...
CytoDyn Inc. (OTCMKTS: CYDY) announced excellent preliminary results from its Phase 1b/2 clinical trial in metastatic triple negative breast cancer...
CytoDyn Inc. (OTMKTS: CYDY) announced discussions with 3 regulatory agencies after an unblinding of the data on February 22, 2021, and the...
Yesterday CytoDyn Inc. (OTCMKTS: CYDY) moved up 27% on the completion of a Memorandum of Understanding with the NIH of Mexico to...
Sell first analyze later mentality of investors oblivious to the increased likelihood of a BLA approval may cost them handsome upside CytoDyn...